Submitted by Anonymous (not verified) on 20 November 2023 - 13:13
Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Multiple Sclerosis, Date of authorisation: 27/06/2006, Revision: 41, Status: Authorised
Source: